Ocular Therapeutix, Inc. Common Stock (OCUL) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with OCUL
Recent news

Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
OCUL

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
OCUL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 34.30
- MACD 12/26/9
- -0.83
- EMA 9 of MACD
- -0.64
- MACD histogram
- -0.19
- SMA 50
- $9.67
- Price below SMA 50
- EMA 50
- $9.27
- Price below EMA 50
- SMA 200
- $9.50
- Price below SMA 200
- EMA 200
- $9.92
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
OCUL

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
OCUL

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
OCUL

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
OCUL

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
OCUL

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
OCUL

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
OCUL

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
OCUL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Ocular Therapeutix, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO | 1964 |
| Mr. Donald Notman Jr. | Chief Operating Officer (Leave of Absence) | — |
| Mr. Steve Meyers | Chief Commercial Officer | — |
| Mr. Sanjay Nayak MBBS, Ph.D. | Chief Strategy Officer | 1970 |
| Dr. Nadia K. Waheed M.D., M.P.H. | Chief Medical Officer | 1977 |
| Mr. Jason Robins | CFO & Principal Accounting Officer | 1977 |
| Dr. Peter K. Jarrett Ph.D. | Chief Technical Officer | 1957 |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer | 1961 |
| Mr. William S. Slattery Jr. | Vice President of Investor Relations | — |
| Mr. Todd D.C. Anderman J.D. | Chief Legal Officer & Corporate Secretary | 1982 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 34.30
- MACD 12/26/9
- -0.83
- EMA 9 of MACD
- -0.64
- MACD histogram
- -0.19
- SMA 50
- $9.67
- Price below SMA 50
- EMA 50
- $9.27
- Price below EMA 50
- SMA 200
- $9.50
- Price below SMA 200
- EMA 200
- $9.92
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $18.00
- Average
- $22.00
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -41.0 | -3.4 | +10.3 | |||||||||
| 2022 | -23.0 | -2.6 | -10.0 | -26.4 | -21.4 | +32.2 | +9.5 | +18.4 | -21.4 | -11.7 | -19.9 | -7.9 |
| 2023 | +40.1 | +56.1 | -13.2 | +18.3 | +3.6 | -19.6 | -9.2 | -13.9 | -18.9 | -3.4 | -22.3 | +66.4 |
| 2024 | +1.0 | +91.6 | -15.3 | -45.5 | +13.5 | +24.1 | +27.0 | +9.3 | +4.2 | +16.2 | -4.8 | -12.6 |
| 2025 | -11.9 | -5.4 | +23.6 | +26.9 | -6.1 | +14.4 | +27.3 | +2.4 | -8.0 | +5.6 | +6.5 | +3.7 |
| 2026 | -22.7 | -2.3 | -22.9 | +12.5 | -4.5 | +10.0 | -13.7 | +24.9 | -27.4 | -0.8 |



